• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Oncology Groups Rally for Cancer Patient Inclusion in COVID-19 Vaccine Trials

Oncology Groups Rally for Cancer Patient Inclusion in COVID-19 Vaccine Trials

June 28, 2021

The American Society of Clinical Oncology and Friends of Cancer Research have called on sponsors to begin including cancer patients in their COVID-19 vaccine trials unless there’s a potential safety risk.

According to the groups, COVID-19 vaccine trials have thus far “almost universally excluded” patients receiving treatment for cancer, while a large number have excluded patients with a history of cancer or those older than 65. Some trial exclusion criteria disqualified patients if they had a history of cancer (except nonmelanoma skin cancers), received cytotoxic or immune-modulating treatment in the past six months, or received systemic corticosteroids, they said.

Current federal guidelines recommend that patients across the cancer spectrum receive COVID-19 vaccinations unless there’s a possible risk to patient safety, but their recommendations are backed by expert consensus, not actual clinical evidence, according to the advocacy groups.

“Narrower, more homogenous patient populations may have been preferable in early-stage vaccine development to avoid compromising approval of potentially viable therapies. However, with multiple vaccines authorized for emergency use by the FDA and other national entities, as well as growing data on the safety profile of novel vaccines, eligibility should be expanded to include patients with cancer, a history of cancer and cancer-related immunologic deficiencies,” they said.

Before the pandemic, the groups were already engaged in similar work to expand and modernize cancer research eligibility criteria with the end goal of making trials more accessible to patients. For example, the pair assembled a working group to examine eligibility criteria for cancer trials, looking at criteria such as brain metastases, minimum age requirements, HIV/AIDS status, organ dysfunction and prior and current malignancies.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing